Showing results (81-90 of 230) with videos related to
Sort By:
Pageof 23
Integrative Cancer Therapies|May 21, 2010
Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patientsElizabeth Dean-Clower, Anne M Doherty-Gilman, Aparna Keshaviah, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 14, 2025
Ovarian Sex Cord Tumor With Annular Tubules (SCTAT) Harbor Recurrent Copy Number Alterations, Including Monosomy 22Andrew M Leader, Alexander Neil, Stephanie Siegmund, et al.Gynecologic Oncology|July 2, 2024
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysisJaclyn A Wall, Rachel A Pozzar, Andrea C Enzinger, et al.Gynecologic Oncology|May 24, 2019
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancerJoyce F Liu, Kathryn P Gray, Alexi A Wright, et al.Gynecologic Oncology|November 2, 2005
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancerMichael V Seiden, Alan N Gordon, Diane C Bodurka, et al.Gynecologic Oncology|November 24, 2020
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancerHuma Q Rana, Lindsay Kipnis, Kristin Hehir, et al.Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion StudyKathleen N Moore, Lainie P Martin, David M O'Malley, et al.Gynecologic Oncology Reports|July 18, 2025
Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcomaStephanie Cham, Niya Xiong, Nabihah Tayob, et al.Gynecologic Oncology|December 28, 2018
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group studyUrsula A Matulonis, Michael W Sill, Vicky Makker, et al.Pageof 23